title: Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Ianotto
authors.forename: Adrian
authors.initials: A
authors.lastname: Tempescul
authors.forename: Yolande
authors.initials: Y
authors.lastname: Amet
authors.forename: Pauline
authors.initials: P
authors.lastname: Grall
authors.forename: Florence
authors.initials: F
authors.lastname: Dalbies
authors.forename: Jean-Richard
authors.initials: JR
authors.lastname: Eveillard
authors.forename: Gaelle
authors.initials: G
authors.lastname: Guillerm
authors.forename: Christian
authors.initials: C
authors.lastname: Berthou
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D016723:Bone Remodeling / Q000187:drug effects; D005198:Fanconi Syndrome / Q000139:chemically induced* / Q000503:physiopathology; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000139:chemically induced / Q000652:urine; D017674:Hypophosphatemia / Q000139:chemically induced; D000068877:Imatinib Mesylate; D007687:Kidney Tubules, Proximal / Q000187:drug effects / Q000503:physiopathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D010879:Piperazines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D012074:Remission Induction; D000608:Renal Aminoacidurias / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate